Reviewer’s report

Title: Rheumatoid arthritis and primary biliary cirrhosis a rare association treated with rituximab: a case report

Version: 4 Date: 5 February 2013

Reviewer: guidog Valesini

Which of the following following best describes what type of case report this is?: Other

If other, please specify:

A new treatment of overlapping diseases

Has the case been reported coherently?: Yes

Is the case report authentic?: Yes

Is the case report ethical?: Yes

Is there any missing information that you think must be added before publication?: No

Is this case worth reporting?: Yes

Is the case report persuasive?: Yes

Does the case report have explanatory value?: Yes

Does the case report have diagnostic value?: No

Will the case report make a difference to clinical practice?: Yes

Is the anonymity of the patient protected?: Yes

Comments to authors:

Interesting case suitable for publication.

The following frases need a revision:

<< During the first treatment with infliximab, we observed a poor clinical response and persistence of abnormal liver function tests. Following the discontinuation of infliximab, the alkaline phosphatase decreased and reached
almost normal values during that etanercept was started. This case shows that etanercept has maintained liver enzymes within normal and controlled arthritis during follow-up of 30 months compared with infliximab did not show similar results [13].

**Quality of written English:** Acceptable